Avara Pharmaceutical Services, a contract development and manufacturing organization (CDMO), has agreed to acquire the Liscate sterile manufacturing plant from Pfizer in Italy.
Avara Pharmaceutical Services chairman and CEO Timothy Tyson said: "This acquisition is an important component of our strategic plan and expands our services by adding sterile processing capability, which is in very high demand.”
Avara Pharmaceutical Services offers API formulation, manufacturing, secondary formulation, small molecule drugs packaging services.
The secondary manufacturing technologies of Avara include granulation, coating, blending, encapsulation, compression and drying of tablets and capsules.
With the acquisition of the new site in Italy, Avara will have six sites with two in the US, one in Puerto Rico, one in the UK and one in Ireland.
Of the two sites located in the US, one facility which is situated in Norwalk will serve as the firm’s corporate headquarters and the other facility in Norman will be used for secondary manufacturing and packaging.
The site located in Arecibo site in Puerto Rico will be used as secondary manufacturing and packaging facility. The Avlon site in the UK and the Shannon site in Ireland will serve as API formulation and manufacturing plant.
Tyson said: "As we celebrate another important milestone, we continue with great confidence to build a pharmaceutical services company with complementary offerings in key regions in this rapidly growing market.
“Each site has significant professional experience, state of the art capability and a long history of delivering high quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements in every major market around the world.
“The people who are a part of the Avara team are the key to our long-term success. We are focused on delivering on our commitments and earning the trust of every customer we deal with."
Image: Avara Pharmaceutical Services to takeover sterile production facility from Pfizer in Italy. Photo: Courtesy of PR Newswire/Avara Pharmaceutical Services, Inc.